

Unless otherwise defined in this announcement, terms defined in the prospectus dated 26 June 2014 (the “**Prospectus**”) issued by Luye Pharma Group Ltd. (the “**Company**”) shall have the same meanings when used in this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement is not, and is not intended to be, an offer of securities of the Company for sale in the United States. The securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. There is not, and is not intended to be, any public offering of the securities described in this announcement in the United States.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 2186)

FULL EXERCISE OF OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option has been fully exercised by the Joint Global Coordinators for themselves and on behalf of the International Purchasers and the Joint Bookrunners on 15 July 2014 to require the Selling Shareholders to sell 149,946,000 additional Shares, representing in aggregate 15% of the number of Offer Shares initially offered under the Global Offering to cover over-allocations in the International Offering.

The Over-allotment Shares will be sold by the Selling Shareholders at HK\$5.92 per Share (excluding brokerage of 1%, SFC transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering.

Further announcement will be made by the Company after the end of the stabilisation period.

The Company announces that the Over-allotment Option has been fully exercised by the Joint Global Coordinators for themselves and on behalf of the International Purchasers and the Joint Bookrunners on 15 July 2014 to require the Selling Shareholders to sell 149,946,000 additional Shares (the “**Over-allotment Shares**”), representing in aggregate 15% of the number of Offer Shares initially offered under the Global Offering to cover over-allocations in the International Offering.

The Over-allotment Shares will be sold by the Selling Shareholders at HK\$5.92 per Share (excluding brokerage of 1%, SFC transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering.

Listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange.

The shareholding structure of the Company immediately before and after the sale of the Over-allotment Shares by the Selling Shareholders is as follows:

Shareholders	Immediately before the sale of the Over-allotment Shares		Immediately after the sale of the Over-allotment Shares	
	<i>Number of Shares</i>	<i>Approximate % of issued share capital</i>	<i>Number of Shares</i>	<i>Approximate % of issued share capital</i>
Luye Pharmaceutical Investment Co., Ltd.	1,509,819,930	45.4%	1,459,999,930	44.0%
CPE Greenery Ltd.	224,223,354	6.8%	196,561,695	5.9%
CDH Flower Limited	212,113,258	6.4%	185,945,579	5.6%
Beyond Border Investment Limited	179,480,448	5.4%	157,338,566	4.7%
Tropical Excellence Infrastructure Pte. Ltd.	195,796,853	5.9%	171,642,073	5.2%
Other Public Shareholders	999,640,000	30.1%	1,149,586,000	34.6%
Total	<u>3,321,073,843</u>	<u>100%</u>	<u>3,321,073,843</u>	<u>100%</u>

As shown in the shareholding structure of the Company set out above, immediately before the exercise of the Over-allotment Option, approximately 54.6% of the issued share capital of the Company was held by public shareholders, such shareholding percentage will be increased to approximately 56.0% immediately upon the exercise of the Over-allotment Option. The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

The Company estimates that the Selling Shareholders will receive additional net proceeds of approximately HK\$862.7 million for the sale of the Over-allotment Shares, after deducting the fees and commissions and expenses payable by the Selling Shareholders in relation to the sale of the Over-allotment Shares. The Company will not receive any of the net proceeds from the sale of the Over-allotment Shares by the Selling Shareholders.

Further announcement will be made by the Company after the end of the stabilisation period in connection with the Global Offering pursuant to Section 9(2) of the Securities and Futures (Price Stabilising) Rules (Cap 571W of the Laws of Hong Kong).

By order of the Board of Directors
Luye Pharma Group Ltd.
Liu Dian Bo
Executive Chairman

Hong Kong, 15 July 2014

As at the date of this announcement, the Executive Directors are Mr. LIU Dian Bo, Mr. YUAN Hui Xian, Mr. YANG Rong Bing and Ms. ZHU Yuan Yuan; the Non-Executive Directors are Mr. PAN Jian, Mr. LIU Dong and Ms. WANG Xin; and the Independent Non-Executive Directors are Mr. ZHANG Hua Qiao, Prof. LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.